{"type":"trials","record":{"id":87191,"source_id":"isrctn","external_id":"ISRCTN12980412","title":"Randomised controlled trial of bevacizumab in choroidal neovascularisation secondary to age-related macular degeneration","brief_summary":"This study has been designed to compare the difference in central macular thickness at one year between two different treatment regimes. Group 1 has an intravitreal bevacizumab injection at week 0 and is observed 6 weekly with repeat injections as required. Group 2 has an intravitreal bevacizumab injection at week 0, 6 and 12 and is observed 6 weekly with repeat injections as required.","overall_status":"Completed","phases":[],"study_type":"Interventional","sponsor":"Frimley Park Hospital NHS Trust (UK)","enrollment":100,"countries":["United Kingdom","England"],"start_date":"2006-11-01","completion_date":"2008-11-01","last_update_date":"2013-08-22","source_url":"https://www.isrctn.com/ISRCTN12980412","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T03:46:39.792962+00:00","last_seen_at":"2026-09-25T03:46:39.551+00:00","metadata":{"sex":"All","age_range":"Adult","comparator":null,"attribution":"Source: ISRCTN ISRCTN12980412; retrieved 2026-09-25","interventions":["Bevacizumab (Avastin)","Drug"],"reuse_license":"Registry contribution CC BY 4.0; generated metadata CC0","registry_source":"ISRCTN","outcome_measures":["Central macular thickness at baseline, Week 6, 12, 18, 24, 30, 36, 42, 48 and 54","1. Visual acuity at baseline, Week 6, 12, 18, 24, 30, 36, 42, 48 and 54 2. Fluorescein angiography changes at baseline,…"],"design_description":"Interventional","source_has_results":false},"controlled_terms":["Age-related macular degeneration","Participants will be randomised to the two treatment groups. Group 1 has an intravitreal bevacizumab (Avastin®) injecti…","results","Bevacizumab (Avastin)","Drug"],"relevance_confidence":100,"source_quality_score":98,"freshness_score":35,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T03:46:42.633202+00:00","duplicate_cluster_key":"id:isrctn12980412","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2006-11-01 to 2008-11-01","comparator":null,"confidence":"structured-source","population":"All · Adult","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T03:46:39.597Z","intervention":["Bevacizumab (Avastin)","Drug"],"participants":100,"study_design":"Interventional","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Central macular thickness at baseline, Week 6, 12, 18, 24, 30, 36, 42, 48 and 54","1. Visual acuity at baseline, Week 6, 12, 18, 24, 30, 36, 42, 48 and 54 2. Fluorescein angiography changes at baseline,…"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as Interventional."],"matched_fields":["title","controlled terminology","title context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ISRCTN Registry","homepage_url":"https://www.isrctn.com/"}},"canonical_url":"https://www.immortal.life/trials/87191","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}